Common questions about Sustiva (FAQ)
Q: Is Sustiva considered a cure for HIV infection?
A: According to official product information, Efavirenz (Sustiva) is not considered a cure for HIV infection. It works by controlling the virus and decreasing the amount of HIV in the blood, which helps maintain immune health over time.
Q: Can Sustiva alone prevent the spread of HIV to others?
A: Regulatory information indicates that taking this medication as part of a combination regimen, along with making other recommended changes, can decrease the risk of transmitting the HIV virus to others. The drug’s approval is specifically for use as part of a combination therapy plan.
Q: What does the 'viral load' mean in the context of taking Sustiva?
A: Viral load is a medical measurement that refers to the amount of HIV circulating in the blood. The primary purpose of Sustiva, as noted in official documents, is to significantly reduce this viral load to undetectable levels.
Q: Is Sustiva used only for treatment, or does it have other purposes?
A: While primarily used for treating HIV-1 infection, official drug information also notes that Efavirenz is used in combination with other medicines for Post-Exposure Prophylaxis (PEP). This is a treatment used to help prevent infection in people who have been recently exposed to the virus.
Q: How does Sustiva help the immune system?
A: By decreasing the amount of virus in the blood, the medication is intended to reduce damage to the immune system. This action supports immune function and is associated with a lower chance of developing HIV-related illnesses or Acquired Immunodeficiency Syndrome (AIDS).
Q: How does Sustiva potentially affect concentration and focus?
A: Official adverse reaction reports list difficulty concentrating as a central nervous system side effect that has been associated with taking Efavirenz. This effect, along with others like dizziness, is typically most noticeable when first starting the medication.
Q: Is there a known connection between Sustiva and changes in mood, such as anxiety?
A: Yes, official reports classify anxiety as a possible neuropsychiatric side effect associated with the use of Efavirenz. Other related mood changes, including depression, have also been reported.
Q: How often do people report feeling depressed while taking Sustiva?
A: Depression, which may become severe, has been reported in patients taking Efavirenz. Regulatory warnings note that psychiatric problems, including depression, are considered serious and have been associated with its use.
Q: What are the official warnings about severe mental health problems linked to Sustiva?
A: Official warnings highlight several severe psychiatric problems associated with the medication. These include severe depression, aggression, and psychosis-like symptoms such as abnormal thinking and delusions. These symptoms are considered serious and require attention.
Q: Can Sustiva cause temporary feelings of confusion or disorientation?
A: Official drug information notes that confusion is a central nervous system side effect that has been associated with the use of Efavirenz. Like other similar side effects, it may be temporary and is often managed by taking the medication at bedtime.
Q: What signs of liver problems are mentioned in official drug documents for Sustiva?
A: Regulatory documents list several signs of potential liver problems that should be monitored. These may include the yellowing of the skin or whites of the eyes (jaundice), unusually dark urine, pain on the right side of the stomach, and a loss of appetite.
Q: Does Sustiva commonly cause gastrointestinal issues like nausea or diarrhea?
A: Nausea, vomiting, and diarrhea are listed among the common adverse reactions reported in clinical trials. These effects are typically observed early in therapy and may lessen over the first few weeks.
Q: What is known about the relationship between Sustiva and bone health?
A: Official research and published reports describe an association between Efavirenz and changes in how the body processes vitamin D due to its effects on liver enzymes. This metabolic change may be associated with decreased bone density over time.
Q: Is a low-grade fever possible when the immune system begins to recover on Sustiva (IRIS)?
A: The official product label warns about the risk of Immune Reconstitution Inflammatory Syndrome (IRIS). This is an inflammatory reaction that can occur as the immune system begins to recover its function, sometimes resulting in a fever or new, unexpected symptoms.
Q: What types of skin rash are officially linked to Sustiva?
A: A general skin rash is a very common adverse event reported in the first two weeks of therapy. However, the product label also warns of rare but serious reactions, including severe cutaneous events like Stevens-Johnson syndrome (SJS).
Q: What is 'lipodystrophy' and is it associated with Sustiva?
A: Lipodystrophy, or 'fat redistribution syndrome,' refers to changes in the way the body stores fat. Official warnings state that this syndrome has been associated with Efavirenz and other HIV medicines, potentially causing fat loss from the face and limbs or fat gain around the trunk.
Q: Are there specific long-term physical changes associated with taking Sustiva?
A: The official drug information states that long-term exposure to Efavirenz is associated with specific metabolic effects. These include dyslipidemia (elevated levels of fats in the blood, like cholesterol and triglycerides) and changes in body fat distribution (lipodystrophy).
Q: Why is Sustiva generally recommended to be taken at bedtime?
A: The official administration guidelines suggest taking Efavirenz at bedtime. This practice is recommended because it may help reduce the daily inconvenience of certain central nervous system (CNS) side effects, such as dizziness or drowsiness, by allowing them to occur while sleeping.
Q: Does Sustiva interact with hormonal birth control methods?
A: Yes, regulatory documents indicate that Efavirenz can significantly lower the levels of the progestogen components in some hormonal contraceptives. This can impair the effectiveness of the birth control, and official guidance indicates the need for an additional reliable barrier method of contraception.
Q: Are there specific over-the-counter medicines or supplements that should not be combined with Sustiva?
A: The herbal supplement St. John's wort is listed as a formal contraindication and is formally contraindicated for use with Efavirenz. Official warnings also advise avoiding co-administration with other medications known to prolong the QTc interval (which affects heart rhythm).
Q: What is the general information about consuming alcohol while taking Sustiva?
A: Official patient information indicates that the central nervous system side effects of Efavirenz, such as dizziness or confusion, may become worse if alcohol or certain mind-altering drugs are consumed. Official guidance notes that regular alcohol consumption may increase the risk of adverse effects, particularly concerning liver damage.
Q: Does the use of recreational substances interact with Sustiva's central nervous system side effects?
A: Yes, official warnings advise that the nervous system side effects of Efavirenz may be worsened if certain street drugs are used during treatment.
Q: Which class of prescription drugs are most likely to interact significantly with Sustiva?
A: Efavirenz significantly interacts with drugs that are mainly metabolized by the Cytochrome P450 (CYP) enzyme system in the liver, particularly an enzyme called CYP3A4. This is because Efavirenz can speed up the activity of these enzymes, lowering the concentration of other co-administered drugs.
Q: Is Sustiva generally used for people with a history of mental health conditions?
A: Official warnings state that individuals with a history of psychiatric problems may be at greater risk for developing serious psychiatric side effects. The medication must be used with caution in these populations and requires careful monitoring.
Q: Can people with pre-existing liver conditions, like Hepatitis C, take Sustiva?
A: Official labeling states that Efavirenz is not recommended for individuals with moderate or severe hepatic impairment (poor liver function). For those with co-infections like Hepatitis B or C, the antiretroviral regimen selection requires special consideration due to potential drug interactions and overlapping risks to the liver.
Q: Is there a difference between the brand name Sustiva and the generic efavirenz?
A: Sustiva is the former brand name for the active drug component, Efavirenz. Generic versions, which contain the identical active ingredient, have been approved by the FDA and are considered therapeutically equivalent to the brand-name product.
Q: Are there studies comparing a lower dose of efavirenz (e.g., 400 mg) to the standard dose?
A: Yes, studies have been conducted to investigate a reduced 400 mg dose compared to the standard 600 mg dose. Evidence has suggested comparable efficacy with reports of fewer drug-related side effect discontinuations at the lower dose.
Q: What are the research findings regarding the durability of Sustiva treatment over time?
A: Long-term data gathered from observational databases have suggested high durability for Efavirenz-based regimens over several years. These findings indicate low rates of virological failure and treatment switching compared to some other older antiretrovirals.
Q: Is Sustiva still considered a first-line treatment option in current global guidelines?
A: As of recent updates to global health organization guidelines, an Efavirenz 600 mg-based regimen has been recommended as a preferred first-line option. Newer regimens have also been recommended as alternative or preferred options in various guidelines.
